American Kidney Fund Launches APOL1 Coalition to Combat Genetic Kidney Disease

Event summary

  • American Kidney Fund (AKF) established the APOL1 Coalition, a multi-year project to centralize resources and strengthen collaboration on APOL1-Mediated Kidney Disease (AMKD).
  • AKF marked the third annual AMKD Awareness Day on April 28, 2026, with support from Vertex Pharmaceuticals and AstraZeneca.
  • The coalition includes leading patient advocates, scientists, industry members, and professional organizations.
  • An estimated 13% of Black Americans have two APOL1 variants, carrying a roughly 1 in 5 risk of developing kidney disease.

The big picture

The launch of the APOL1 Coalition underscores the growing recognition of AMKD as a critical health issue, particularly among Black and Hispanic/Latino communities. With increasing industry and advocacy collaboration, the focus on genetic kidney disease research and awareness is poised to accelerate. The strategic partnerships with Vertex Pharmaceuticals and AstraZeneca highlight the potential for targeted therapeutic advancements in this space.

What we're watching

Coalition Effectiveness
Whether the APOL1 Coalition can sustain momentum and drive meaningful advancements in AMKD research and treatment.
Awareness Impact
The pace at which AMKD awareness campaigns translate into early detection and proactive health management in at-risk communities.
Industry Collaboration
How pharmaceutical partnerships with AKF will influence the development of targeted therapies for AMKD.